UMPS
ENSG00000114491
Target class
Enzyme
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- UMPS
- Gene name
- Uridine monophosphate synthetase
- Gene symbol
- UMPS
- Protein name
- Uridine 5'-monophosphate synthase (UMP synthase) [Includes: Orotate phosphoribosyltransferase (OPRT) (OPRTase) (EC 2.4.2.10); Orotidine 5'-phosphate decarboxylase (ODC) (OMPD) (EC 4.1.1.23) (OMPdecase)]
- OPRT
- ODC
- Gene biotype
- Protein coding
- Gene family
- MicroRNA protein coding host genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 15.89
- Tissue specificity (Gini)
- 0.277
- Tissue specificity (tau)
- 0.658
- KEGG gene identifiers
- hsa:7372
- Reactome pathways
- R-HSA-500753
- Protein interaction confidence
- 0.876529
- Protein interaction partners
- 68
- End position
- 124749273
- Start position
- 124730433
- Chromosome
- 3
- Strand
- Forward
- Cytosol
- Tissue specificity (tau)
- 0.657611
- Expression inequality (Gini)
- 0.276671
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 15.89
- Cells - Cultured fibroblasts
- 15.57
- Esophagus - Mucosa
- 9.55
- Skin - Sun Exposed (Lower leg)
- 9.07
- Skin - Not Sun Exposed (Suprapubic)
- 8.46
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes15.89
- Cells - Cultured fibroblasts15.57
- Esophagus - Mucosa9.55
- Skin - Sun Exposed (Lower leg)9.07
- Skin - Not Sun Exposed (Suprapubic)8.46
- Spleen8.33
- Fallopian Tube8.28
- Testis7.82
- Uterus7.78
- Ovary7.65
- Adrenal Gland7.64
- Nerve - Tibial7.56
- Cervix - Endocervix7.37
- Vagina7.15
- Breast - Mammary Tissue6.91
- Thyroid6.9
- Small Intestine - Terminal Ileum6.74
- Cervix - Ectocervix6.58
- Bladder6.29
- Adipose - Subcutaneous6.27
- Brain - Cerebellum6.26
- Brain - Cerebellar Hemisphere6.21
- Minor Salivary Gland6.09
- Colon - Transverse6.01
- Liver5.83
And 29 more, listed on the interactive page.
Biological processes
- GO:0006222
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0004588
- GO:0004590
- GO:0005515
Related records
Trials (40)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
- A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
- A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
- Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer
- Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer
- Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
- DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
- Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
- Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer
- Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
- Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer
- Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
- Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Drugs (2)
- Azaribine Uridine 5'-monophosphate synthase inhibitor
- Oteracil